Company Encyclopedia
View More
name
Newland
301277.SZ
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium.
3.159 T
301277.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking147/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.16%B
    • Profit Margin18.45%A
    • Gross Margin31.40%C
  • Growth ScoreD
    • Revenue YoY-4.03%D
    • Net Profit YoY-24.61%D
    • Total Assets YoY0.25%C
    • Net Assets YoY0.69%C
  • Cash ScoreC
    • Cash Flow Margin541.90%C
    • OCF YoY-4.03%D
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio12.74%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Newland: Signed a cooperation agreement for GLP-1 class long-acting peptide innovative drugs

    Newland announced that the company recently signed a cooperation development and licensing agreement with Nanjing Zhihe Pharmaceutical Technology Co., Ltd. The two parties will carry out strategic cooperation in the field of GLP-1 class long-acting peptide innovative drugs. The cooperation includes drug research and development, production, commercialization, and external transactions. The signing of this agreement does not constitute a related party transaction, nor does it constitute a major asset reorganization, and it does not meet the review standards of the company's board of directors and shareholders' meeting. The agreement does not involve specific amounts and will not have a significant impact on the company's financial status, operating results, and performance for this year

    Zhitong·
    SZ
    301277
    +0.16%
    Zhitong·
    SZ
    301277
    +0.16%

    Newland released its performance for the first three quarters, with a net profit attributable to the parent company of 91.907 million yuan, a decrease of 35.19%

    Newland released its Q3 2025 report, with operating revenue for the first three quarters at 481 million yuan, a year-on-year decrease of 10.42%; net profit attributable to the parent company was 91.907 million yuan, a year-on-year decline of 35.19%; net profit excluding non-recurring gains and losses was 83.6323 million yuan, a year-on-year decrease of 36.65%; basic earnings per share were 0.2344 yuan

    Zhitong·
    SZ
    301277
    +0.16%
    Zhitong·
    SZ
    301277
    +0.16%

    Newland released its semi-annual performance, with a net profit attributable to the parent company of 78.03 million yuan, a year-on-year decrease of 30.01%

    Newland released its 2025 semi-annual performance, with revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the parent company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan. Despite the overall decline in performance, revenue from toluenesulfonic acid increased by 13.16% year-on-year, and the company has competitive advantages in the pharmaceutical and high-purity markets, actively expanding into high-end application fields

    Zhitong·
    SZ
    301277
    +0.16%
    Zhitong·
    SZ
    301277
    +0.16%

    Newland has obtained a drug registration certificate

    Newland recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, which pertains to the drug Vildagliptin tablets, suitable for the treatment of type 2 diabetes. Vildagliptin, as a selective DPP-4 inhibitor, can rapidly inhibit DPP-4 activity, increase endogenous GLP-1 and GIP levels, thereby enhancing β-cell sensitivity to glucose, promoting insulin secretion, and lowering blood glucose levels

    Zhitong·
    SZ
    301277
    +0.16%
    Zhitong·
    SZ
    301277
    +0.16%

    23 stocks closed at a historic high

    Excluding newly listed stocks in the past year, a total of 23 stocks closed at historical highs today. From the perspective of industry attributes, stocks in the machinery equipment, pharmaceutical and biotechnology, and food and beverage industries are relatively concentrated at new highs, with 6, 5, and 2 stocks appearing on the list, respectively. Among the stocks that closed at historical highs, the average price increase today was 6.98%, with limit-up stocks including HIT WELDING, JLY Group, and ZHEJIANG JINGHUA LASER TECHNOLOGY. The top gainers included Sunshine Guojian Pharmaceutical, Changshan Pharmaceutical, and Newland

    Zhitong·
    SZ
    002882
    +0.70%
    SH
    688336
    -0.52%
    SZ
    301277
    +0.16%
    Zhitong·
    SZ
    002882
    +0.70%
    SH
    688336
    -0.52%
    SZ
    301277
    +0.16%
    © 2025 Longbridge｜Disclaimer